Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 115

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 115
---
)$(822,649)(16,216,411)$(802,486)$811,019 Unrealized loss on available-for-sale securities— — — (646)— — — (646)Common stock issued under stock incentive plan and ESPP806,433 1 5,863 — — — — 5,864 Stock-based compensation expense— — 9,234 — — — — 9,234 Net loss— — — — (81,549)— — (81,549)Balance at March 31, 202472,967,922 $73 $2,451,620 $(1,087)$(904,198)(16,216,411)$(802,486)$743,922 Unrealized gain on available-for-sale securities— — — 42 — — — 42 Common stock issued under stock incentive plan and ESPP123,568 — 1,099 — — — — 1,099 Stock-based compensation expense— — 11,565 — — — — 11,565 Net loss— — — — (96,118)— — (96,118)Balance at June 30, 202473,091,490 $73 $2,464,284 $(1,045)$(1,000,316)(16,216,411)$(802,486)$660,510 

See accompanying Notes to Condensed Consolidated Financial Statements.

4

AGIOS PHARMACEUTICALS, INC.Condensed Consolidated Statements of Cash Flows(Unaudited)Six Months EndedJune 30,(In thousands)20252024Operating activitiesNet loss$(201,309)$(177,667)Adjustments to reconcile net loss from operations to net cash used in operating activities:Depreciation and amortization2,537 2,941 Stock-based compensation expense26,051 20,799 Net accretion of discount on marketable securities(3,768)(5,136)Loss (gain) on disposal of property and equipment5 (39)Non-cash operating lease expense6,094 5,659 Expense associated with license agreement10,000 — Realized gain on investments(2)(153)Changes in operating assets and liabilities: